1. Shin CS, Choi HJ, Kim MJ, et al. Prevalence and risk factors of osteoporosis in Korea: a community-based cohort study with lumbar spine and hip bone mineral density. Bone 2010;47:378-387.
2. Choi YJ, Oh HJ, Kim DJ, et al. The prevalence of osteoporosis in Korean adults aged 50 years or older and the higher diagnosis rates in women who were beneficiaries of a national screening program: the Korea National Health and Nutrition Examination Survey 2008-2009. J Bone Miner Res 2012;27:1879-1886.
5. Lee YK, Lee YJ, Ha YC, et al. Five-year relative survival of patients with osteoporotic hip fracture. J Clin Endocrinol Metab 2014;99:97-100.
6. Yoon HK, Park C, Jang S, et al. Incidence and mortality following hip fracture in Korea. J Korean Med Sci 2011;26:1087-1092.
8. Kang BJ, Lee YK, Lee KW, et al. Mortality after hip fractures in nonagenarians. J Bone Metab 2012;19:83-86.
10. Tsuboi M, Hasegawa Y, Suzuki S, et al. Mortality and mobility after hip fracture in Japan: a ten-year follow-up. J Bone Joint Surg Br 2007;89:461-466.
11. Borgquist L, Ceder L, Thorngren KG. Function and social status 10 years after hip fracture. Prospective follow-up of 103 patients. Acta Orthop Scand 1990;61:404-410.
12. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243-254.
13. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-2026.
14. Hochberg MC, Thompson DE, Black DM, et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005;20:971-976.
17. Lai MM, Ang WM, McGuiness M, et al. Undertreatment of osteoporosis in regional Western Australia. Australas J Ageing 2012;31:110-114.
23. Harrington JT, Broy SB, Derosa AM, et al. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 2002;47:651-654.
24. Siris ES, Bilezikian JP, Rubin MR, et al. Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab 2003;88:3482-3486.
26. Goeree R, Blackhouse G, Adachi J. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin 2006;22:1425-1436.
29. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-1809.
30. Miki RA, Oetgen ME, Kirk J, et al. Orthopaedic management improves the rate of early osteoporosis treatment after hip fracture. A randomized clinical trial. J Bone Joint Surg Am 2008;90:2346-2353.
32. Majumdar SR, Beaupre LA, Harley CH, et al. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med 2007;167:2110-2115.
34. Mannius S, Mellström D, Odén A, et al. Incidence of hip fracture in western Sweden 1974-1982. Comparison of rural and urban populations. Acta Orthop Scand 1987;58:38-42.
35. Solbakken SM, Magnus JH, Meyer HE, et al. Impact of comorbidity, age, and gender on seasonal variation in hip fracture incidence. A NOREPOS study. Arch Osteoporos 2014;9:191
37. Chiu KY, Ng TP, Chow SP. Seasonal variation of fractures of the hip in elderly persons. Injury 1996;27:333-336.
38. Levy AR, Bensimon DR, Mayo NE, et al. Inclement weather and the risk of hip fracture. Epidemiology 1998;9:172-177.